睿知中国疾病研究地图
候选清单0

正在招募胃癌I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

HS-10502 Combination Treatment in Patients With Advanced Solid Tumors

ClinicalTrials.gov 上登记的一项胃癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心复旦大学附属肿瘤医院Fudan University Shanghai Cancer Center上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06769425,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Patients diagnosed with pathologically confirmed advanced solid tumors.

    入选标准第 2 条

  3. Have received or is currently receiving the following treatment: PARPi/B7-H4/B7-H3-targeted therapies;

    排除标准第 1 条

    Have received or is currently receiving the following treatment: PARPi/B7-H4/B7-H3-targeted therapies;

    排除标准第 2 条

    Have received any of cytotoxic chemotherapy drugs, investigational drugs, anti-tumor traditional Chinese medicines or other anti-tumor drugs within 14 days prior to the first dose of study drug; or need to continue these drugs during the study.

    排除标准第 3 条

    Presence of Grade ≥ 2 toxicities as per Common Terminology Criteria for Adverse Events due to prior anti-tumor therapy.

    排除标准第 4 条

    Have received systemic glucocorticoid therapy for more than 7 days within 28 days prior to the first dose study treatment, or require chronic (≥ 7 days) use of systemic glucocorticoids during the study, or have other acquired, congenital immunodeficiency disorders, or a history of organ transplantation.

    排除标准第 15 条

    Subjects with gastrointestinal fistula, visceral fistula, gastrointestinal perforation, or abdominal abscess, or with symptoms/signs of intestinal obstruction within 6 months prior to the first dose of study drug.

    排除标准第 23 条

  4. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 to 1 and no deterioration within 2 weeks before the first dose.

    入选标准第 4 条

  5. Subjects have at least one target lesion as assessed per the RECIST 1.1.

    入选标准第 3 条

  6. Female subjects must have a negative pregnancy test within 7 days prior to the first dose (for subjects with tumor related abnormal elevation of human chorionic gonadotropin [HCG], an ultrasound of uterus and appendages should be performed within 7 days prior to the first dose to rule out pregnancy), or demonstrate no risk for pregnancy.

    入选标准第 7 条

    Pregnant or breast-feeding women or women who intend to become pregnant during the study.

    排除标准第 20 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;试验排除的其他疾病。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06769425,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Males or females aged 18 years or older (≥18 years).
  2. Patients diagnosed with pathologically confirmed advanced solid tumors.
  3. Subjects have at least one target lesion as assessed per the RECIST 1.1.
  4. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 to 1 and no deterioration within 2 weeks before the first dose.
  5. Have a life expectancy of at least 12 weeks.
  6. Female subjects of childbearing potential are willing to take appropriate contraceptive measures and should not breastfeed from signing the informed consent until 6 months after the last dose; male subjects must agree to use barrier contraception (i.e. condoms) from signing the informed consent to 6 months after the last dose.
  7. Female subjects must have a negative pregnancy test within 7 days prior to the first dose (for subjects with tumor related abnormal elevation of human chorionic gonadotropin [HCG], an ultrasound of uterus and appendages should be performed within 7 days prior to the first dose to rule out pregnancy), or demonstrate no risk for pregnancy.
  8. Subject must be voluntarily enrolled in this clinical trial, be able to understand the study procedures and to sign written informed consent.

排除标准:Exclusion Criteria:

  1. Have received or is currently receiving the following treatment: PARPi/B7-H4/B7-H3-targeted therapies;
  2. Have received or is currently receiving the following treatment: PARPi/B7-H4/B7-H3-targeted therapies;
  3. Have received any of cytotoxic chemotherapy drugs, investigational drugs, anti-tumor traditional Chinese medicines or other anti-tumor drugs within 14 days prior to the first dose of study drug; or need to continue these drugs during the study.
  4. Presence of Grade ≥ 2 toxicities as per Common Terminology Criteria for Adverse Events due to prior anti-tumor therapy.
  5. Presence of pleural/abdominal effusion requiring clinical intervention.
  6. Known history of other primary malignancy.
  7. Evidence of brain metastasis and/or cancerous meningitis
  8. Inadequate bone marrow reserve or hepatic/renal functions.
  9. Cardiological examination abnormality.
  10. Severe, uncontrolled or active cardiovascular disorders.
  11. Serious or poorly controlled diabetes.
  12. Serious or poorly controlled hypertension.
  13. Clinically significant bleeding symptoms or significant bleeding tendency within 1 month prior to the first dose of study treatment.
  14. Serious infections within 4 weeks prior to the first dose.
  15. Have received systemic glucocorticoid therapy for more than 7 days within 28 days prior to the first dose study treatment, or require chronic (≥ 7 days) use of systemic glucocorticoids during the study, or have other acquired, congenital immunodeficiency disorders, or a history of organ transplantation.
  16. Presence of active infectious diseases such as hepatitis B, hepatitis C, tuberculosis, syphilis, or human immunodeficiency virus infection, etc.
  17. Current hepatic encephalopathy, hepatorenal syndrome, or Child-Pugh Class B or more severe cirrhosis.
  18. Any moderate or severe lung diseases that may interfere with the detection and treatment of drug-related pulmonary toxicity or may seriously affect respiratory function.
  19. History of severe neurological or psychiatric disorder.
  20. Pregnant or breast-feeding women or women who intend to become pregnant during the study.
  21. Attenuated live vaccination within 4 weeks prior to the first dose.
  22. Subjects with autoimmune disease that is active or is likely to recur.
  23. Subjects with gastrointestinal fistula, visceral fistula, gastrointestinal perforation, or abdominal abscess, or with symptoms/signs of intestinal obstruction within 6 months prior to the first dose of study drug.
  24. Subjects unlikely to comply with study procedures, restrictions and requirement as determined by the investigator.
  25. Subjects with any condition that jeopardizes the safety of the patient or interferes with the assessment of the study, as judged by the investigator.

引自 ClinicalTrials.gov, NCT06769425, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06769425,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06769425